PRSS22

Across TCGA pan-cancer cohorts, PRSS22 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PRSS22’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PRSS22 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PRSS22 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where PRSS22 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRSS22 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.647	<.001	8	view →
LSCC	All	III,IV	+0.964	<.001	7	view →
LUAD	All	All	+0.232	.013	3	view →
PDAC	All	II,III,IV	+0.749	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PRSS22–HNSC

Open the HNSC breakdown →